Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway
Featuring perspectives from Dr Sara A Hurvitz,
Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr
Nicholas Turner, moderated by Dr Tolaney, including the following
topics:
Introduction (0:00)
Current and Future Roles of
Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective
Estrogen Receptor Degraders (SERDs) in First-Line Therapy for
HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr
Turner (2:35)
Role of Oral SERD
Monotherapy in the Treatment of Progressive HR-Positive,
HER2-Negative mBC — Dr O’Shaughnessy (25:23)
Potential Use of Oral
SERD-Containing Combination Regimens in Managing Progressive
HR-Positive, HER2-Negative mBC — Dr Mayer (46:29)
Clinical Utility of Agents
Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive
HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06)
Potential Use of Oral SERDs
for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney
(1:38:17)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.